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Management of Asymptomatic Severe Aortic Stenosis
Jacob P. Dal-Bianco, MD,* Bjoy K. Khandheria, MBBS, FACC, FASE, FESC,†
Farouk Mookadam, MD, FRCP, MSC,† Federico Gentile, MD,†
Partho P. Sengupta, MBBS, MD, DM†
Rochester, Minnesota; and Scottsdale, Arizona
Patients with symptomatic severe aortic stenosis (AS) benefit from aortic valve replacement (AVR). Management
of severe AS in the absence of symptoms is, however, controversial and often challenging. Unselected prema-
ture AVR carries the risks of cardiac surgery; delayed AVR due to unrecognized symptoms can result in a dismal
outcome. Echocardiography is the standard tool to evaluate and follow patients with AS. Nevertheless, most of
the current echocardiographic parameters have limitations in predicting symptom onset and clinical outcome.
The same applies to clinical parameters, exercise stress testing, and other imaging modalities used in AS evalu-
ation and serial follow-up. Predictors of outcome could, however, help to identify asymptomatic patients who
would benefit from expedited AVR with the goal to reduce mortality. This review will discuss the most relevant
clinical studies and guidelines on management of asymptomatic severe AS, with an emphasis on providing con-
cise information for identifying patients at high risk. (J Am Coll Cardiol 2008;52:1279–92) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.020v
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rvery fourth patient over age 65 years has evidence of aortic
clerosis (1), and more than 4% of the North American
opulation age 75 years and older have aortic stenosis (AS)
2). Approximately 1 in 6 aortic sclerosis patients advances
o AS (3), and in already established mild-to-moderate AS,
ne-half of those affected progress to hemodynamically
evere AS (4).
Survival of patients with symptomatic AS is dismal (5–8),
nd the treatment of choice is aortic valve replacement
AVR) (9). Current AVR indication and timing is largely
ased on the development of angina, dyspnea, or syncope
10), and successful AVR results in good long-term prog-
osis (11,12). However, management of severe AS in the
bsence of symptoms is challenging. Whereas lack of
ymptom recognition portends a high risk of death (13),
nselected, premature AVR is associated with the risks of
ardiac surgery and valve prosthesis complications. At least
very third—with estimates up to every second—patient
ith severe AS is asymptomatic (5,14,15). This makes
eliable risk estimation and appropriate AVR indication and
iming in patients with asymptomatic severe AS a common
nd important clinical challenge.
For this review we searched the MEDLINE database
ith PubMed. Our queries included the Medical Subject
eading term “Aortic Valve Stenosis” in various combina-
ions with “asymptomatic,” “outcome,” “predictor,” “sur-
rom the *Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota;
nd the †Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona.R
Manuscript received May 5, 2008; revised manuscript received June 30, 2008,
ccepted July 1, 2008.ival,” and “mortality.” Search results were restricted to
riginal articles, reviews, and editorials in the English
anguage. Additionally we retrieved articles referenced by
ublished guidelines and comprehensive reviews.
alcific Aortic Valve Disease:
rom Aortic Sclerosis to AS
alcific aortic valve disease is the leading AS etiology in
ndustrialized countries (2,16–18) and shares the athero-
clerosis risk factors age, gender, hypertension, smoking,
erum low-density lipoprotein, and lipoprotein (a) levels (1).
ortic valve calcification is a complex pathological process
hat starts at the base of the aortic cusp (10), primarily in
esponse to endothelial damage caused by blood flow shear
tress, and is followed by inflammatory cell infiltration, lipid
nd calcium deposition, and activation of osteoblast-like
ells (19–25). Disease progression might be potentially
odifiable by anti-inflammatory and lipid-lowering therapy
HMG-CoA reductase inhibitors) (26–30); however, if
rogressive, calcification usually spreads to the leaflet tips
ausing thickening, stiffening, and restricted movement of
he aortic valve leaflets. Calcific aortic valve disease can be
onobstructive ( aortic sclerosis) or obstructive ( AS).
ortic stenosis can be graded, on the basis of the severity of
bstruction, as mild, moderate, or severe (Table 1).
The average time interval from development of aortic
clerosis to moderate and severe AS is 6 and 8 years,
espectively (3). This gives the left ventricle (LV) time to
emodel for counteracting the increase in afterload (31,32).
eduction in LV longitudinal shortening due to subendo-
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Asymptomatic Severe Aortic Stenosis October 14, 2008:1279–92cardial dysfunction (33) is ac-
companied with adaptive con-
centric wall hypertrophy (34) and
exaggerated LV torsional me-
chanics (35) to keep LV systolic
wall stress and left ventricular
ejection fraction (LVEF) initially
within the normal range. Once
moderate AS is present the aver-
age rate of aortic jet velocity pro-
gression by cardiac ultrasound is
0.3 m/s/year, with a concomitant
increase in the mean transvalvu-
lar pressure gradient of 7 mm
Hg/year and a parallel reduction
in aortic valve area (AVA) of 0.1
cm2/year (11,36–38). Hemody-
namic progression and calcifica-
tion are accelerated in patients
with congenital aortic valve dis-
ease (39). Patients with bicuspid
aortic valve disease (BAV)
present for AVR earlier (fourth
decade) in comparison with pa-
tients with tricuspid AS (sixth
decade) (18).
atural History of Asymptomatic AS
oss and Braunwald (40) published a comprehensive report
n the natural history of AS, summarizing prospective and
etrospective (post-mortem) studies and their experience.
atients with AS who developed angina and syncope
urvived 3 years, patients with dyspnea 2 years, and patients
ith heart failure survived 1.5 to 2 years, respectively. This
andmark survival analysis from 1968 included symptomatic
atients with heterogeneous AS etiologies (e.g., bicuspid
S; rheumatic AS [41]), which might limit applicability in
oday’s most common AS etiology—tricuspid calcific AS.
Several retrospective (14,42) and prospective studies
11,43) have subsequently specifically evaluated the progno-
is and management of patients with asymptomatic severe
S. It is important to note that these studies differed in
esign (e.g., patient age, exclusion criteria, mean transval-
ular gradient). For example, Otto et al. (43) included
atients with less than severe AS and bicuspid AS (28% of
he study population). Secondly, AVR was considered as a
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve
replacement
BAV  bicuspid aortic
valve
BNP  brain natriuretic
peptide
CI  confidence interval
CR  contractile reserve
ESC  European Society of
Cardiology
HR  hazard ratio
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
OR  odds ratio
RR  relative risk
S Severity Grading
Table 1 AS Severity Grading
Mild AS Moderate AS Severe AS
AVA (cm2) 1.5 1.5–1.0 1.0
AVA index (cm2/m2) 0.6
Mean gradient (mm Hg) 25 25–40 40
Aortic jet velocity (m/s) 3.0 3.0–4.0 4.0c
dapted from Bonow et al. (10).
AS  aortic stenosis; AVA  aortic valve area.linical end point in each of these studies (Table 2). This
akes survival data less conclusive, because AVR is a “soft”
linical end point compared with cardiac death. Moreover,
eferral for AVR might have been confounded by the
rimary physician’s treatment bias (“pre-emptive” AVR vs.
rue symptom development) or AVR performed concomi-
antly with coronary artery bypass grafting. Thirdly, coro-
ary artery disease was not an exclusion criterion and
otentially confounded cardiac death. Despite these limita-
ions, it is worthwhile noting that approximately one-third
f asymptomatic AS patients become symptomatic within 2
ears (42). Within 4 to 5 years, two-thirds of patients have
ither an AVR due to symptom development or cardiac
eath (11,14,43). Survival in asymptomatic and unoperated
atients is 99%, 98%, and 93% at 1, 2, and 5 years,
espectively. Survival in these patients is actually similar to
n age- and gender-matched healthy population; however,
he prognosis worsens significantly as soon as symptoms
evelop (14). Overall survival of patients with asymptomatic
evere AS including those who have AVR is 93 2%, 91
%, and 87  3% at 1, 2, and 5 years, respectively, which
gain does not differ statistically from an age- and gender-
atched population (11). Early estimates of sudden death
ithout preceding symptoms were approximately 3% to
%/year (40). More recent evidence supports the concept
hat sudden death in truly asymptomatic AS patients is
1%/year (5,7,11,42,43). This conservative number, how-
ver, might be generated by heightened clinical vigilance,
here patients are followed meticulously with serial
chocardiography, and might not be representative of the
mbient annual risk of sudden death in this group of
atients.
iagnosis of AS and Grading of Severity
n the basis of 2-dimensional echocardiography and Dopp-
er measurements, AS can be graded as mild, moderate, and
evere (Table 1) (10,44). In general, aortic jet velocity is the
ost reproducible measurement (45,46), because even small
rrors in LV outflow tract diameter and ultrasound beam
lignment with respect to the aortic jet profoundly influence
he calculated AVA and mean and peak transvalvular
ressure gradient. Significant aortic regurgitation has lim-
ted impact on Doppler-calculated AVA, whereas a chaotic
ubvalvular velocity profile due to subvalvular obstruction
e.g., septal hypertrophy or subaortic membrane) results in
rroneous AVA quantification (47). Furthermore, it needs
o be emphasized that serial echocardiographic evaluation
hould be performed in a state of comparable hemodynamic
ange (46,48), because interexamination blood pressure
ifferences, especially acute hypertension, can mask AS
everity by influencing transvalvular pressure gradient and
et velocity (49).
Because noninvasive transvalvular gradients show excel-
ent correlation with invasive transvalvular gradients, cardiac
atheterization is rarely used to diagnose AS (50). Invasive
Natural History of Patients With Asymptomatic Severe AS
Table 2 Natural History of Patients With Asymptomatic Severe AS
n
Age
(yrs) Exclusion Criteria
Baseline
Aortic Jet
Velocity
(m/s)
Mean
Gradient
(mm Hg) Follow-Up
Symptom
Definition
Cardiac Event/
End Point
Definition
(n if Available)
Symptom-Free Survival
(%)
Event-Free Survival
(%)
1 Yr 2 Yrs 5 Yrs 1 Yr 2 Yrs 3 Yrs 4 Yrs 5 Yrs
Pellikka
et al. (42)
113 70 (40–94) Cardiac symptoms,
multivalvular
involvement,
moderate-to-severe AR,
documented MI, prior
CABG, percutaneous
aortic balloon
valvuloplasty, valve
replacement
4.3 (4–6)*† 47 20 (6–48)
months
Angina,
dyspnea,
syncope
AVR (20),
cardiac
death
second to
AS (3)
86 3 62 6 93 2 74 6
Otto et al.
(43)
123 63 16 Inability to return for
follow-up (severe
comorbid disease,
distance of hospital
from residence),
patient refusal, AVR
within 3 months of
enrollment
3.6 0.6‡ 29 11 2.5 1.4
yrs
Angina, heart
failure,
syncope,
or near
syncope
AVR (48),
cardiac
death (4)
93 5 67 10 34 15
Rosenhek
et al. (11)
128 60 18 Hemodynamically
significant valvular
lesions, symptoms at
presentation
5.0 0.6§ NA 22 18
months
NA AVR (59),
cardiac
death (6),
noncardiac
death (2)
67 5 56 5 33 5
Pellikka
et al. (14)
622 72 11 Multivalvular involvement,
moderate-to-severe AR,
documented MI, prior
CABG/percutaneous
aortic balloon
valvuloplasty/valve
replacement/cardiac
surgery, history of
cardiac symptoms,
patient refusal, referral
to surgery on initial
evaluation
4.4 0.4* 46 11 5.4 4.0
yrs
Angina,
dyspnea,
syncope
Symptom
development
(297),
AVR (352),
cardiac
death (117)
82 67 33 80 63 25
Data presented as mean  SD or as range if indicated. *Peak aortic jet velocity; †aortic jet velocity range; ‡maximum aortic jet velocity; §mean aortic jet velocity.
AR  aortic regurgitation; AS  aortic stenosis; AVR  aortic valve replacement; CABG  coronary artery bypass grafting; MI  myocardial infarction; NA  data not available.
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Asymptomatic Severe Aortic Stenosis October 14, 2008:1279–92emodynamics, however, might be of value in patients in
eed of coronary angiogram whose Doppler-derived
ransvalvular gradients are disproportionate to physical
xam findings or patient history. An example is a patient
ith a small ascending aorta diameter (3 cm) where
ronounced pressure recovery might lead to significant Dopp-
er overestimation of transvalvular gradient and therefore AS
everity (51).
More recently, 3-dimensional echocardiography (52–55),
ardiac computerized tomography (56,57), and cardiac
agnetic resonance imaging (58–60) have been proposed as
dditional techniques to quantify AVA and AS severity.
ecause these imaging modalities measure the anatomic and
ot the functional effective AVA, AS severity is more likely
o be underestimated. A new and exciting magnetic reso-
ance imaging technique, overcoming the limitations of
natomic quantification of the AVA, is velocity-encoded
hase contrast imaging (Fig. 1) (60–62). This method
llows AVA quantification with the continuity equation
imicking echocardiographic Doppler quantification and
hould be helpful in patients with poor echocardiographic
indows, obesity, lung disease, or heavily calcified aortic
alves. Contrary to current “crude” conventional measures
uch as LVEF, tissue Doppler imaging and speckle track
maging (Fig. 2) are superior in detecting subtle changes in
yocardial function. Studies have shown reduced longitu-
inal systolic and early diastolic mitral annular velocities in
atients with AS (63–65) and evidence of early LV systolic
Figure 1 Velocity-Encoded Phase Contrast Magnetic Resonanc
Sampling planes in the left ventricular outflow tract and after the aortic valve allow
(gray area under the curve). Functional aortic valve area is then calculated by conysfunction if peak systolic mitral annular velocity increase
fter treadmill exercise is blunted (66). Longitudinal strain
nd strain rates are also reduced but show significant
mprovements after AVR, even before global LV function
mproves (67). Left ventricular torsion is a measure of the
wringing” motion of the heart and plays a critical role in
fficient blood expulsion and filling. Systolic LV torsion is
reserved or exaggerated in AS (35,68) and likely compen-
ates for depressed intramyocardial circumferential strain
69) and decreased subendocardial contractile function (70)
Fig. 3). Diastolic untwisting is delayed, resulting in ele-
ated LV end-diastolic filling pressures (35,68). Left ven-
ricular torsion normalizes (69) and subendocardial contractile
unction significantly recovers within 3 month after AVR—
ven before LV remodeling is obvious (70). Early detection of
yocardial dysfunction by tissue Doppler and speckle track
maging (Fig. 2) might be therefore potentially useful in
ptimizing the timing of AVR before the onset of global LV
ysfunction and symptoms in patients with severe AS (33).
owever, this requires future investigation.
isk Estimation in Asymptomatic Severe AS
major clinical challenge is to manage asymptomatic
atients with severe AS when the lack of clinical symp-
oms and echocardiographic findings do not support
VR per guidelines. The physician has to weigh the
ndividual patient risks for AVR surgery versus watchful
ging in Aortic Stenosis
urement of quantitative flow by velocity time integration
equation. Adapted, with permission, from Caruthers et al. (62).e Ima
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October 14, 2008:1279–92 Asymptomatic Severe Aortic Stenosisaiting with potential risk of sudden cardiac death or
VR at a more advanced age (71). Identifying at-risk
atients would allow optimized AVR timing and “con-
rolled” anticipation of AVR, while meeting the goals of
voiding unnecessary surgery and improving long-term
ortality. The following section will elucidate the cur-
ent concepts of risk estimation in patients with asymp-
omatic severe AS. Table 3 summarizes the predictors for
ymptoms, outcome, and operative mortality.
redictors of Symptom Development
lectrocardiography. In a multivariate analysis, LV hyper-
rophy defined by Romhilt and Estes criteria (72) was found
o be an independent predictor for the development of
ymptoms in asymptomatic severe AS patients (hazard ratio
HR]: 1.39; 95% confidence interval [CI]: 1.02 to 1.89; p
.04) (14). The sensitivity for detecting LV hypertrophy by
lectrocardiogram, however, might be as low as 40%.
chocardiography. Patients with asymptomatic severe AS
nd a peak aortic jet velocity 4.5 m/s are more likely to
evelop symptoms compared with patients with a peak
ortic jet velocity 4.5 m/s (relative risk [RR]: 1.34; 95%
Figure 2 Longitudinal Left Ventricular Mechanics in Asymptom
Continuous wave Doppler signal across the stenotic aortic valve (A) shows a peak
from the septal corner of the mitral valve annulus (B) shows a reduced peak early
speckle tracking (2D strain, GE Healthcare, Milwaukee, Wisconsin) shows attenua
and basal (blue curve) of the lateral wall of the left ventricle (peak strain values 
from the septum and lateral wall of the left ventricle (global strain  12%). Aa  p
peak systolic velocity during ejection.I: 1.04 to 1.72; p  0.03) (14). The same investigators 0howed that: 1) each 0.2-cm2 decrease in AVA translates
nto an RR of 1.26 likelihood of developing symptoms (95%
I: 1.08 to 1.47; p 0.004); and 2) AVA is an independent
redictor for the development of symptoms (HR: 0.33 for a
-cm2 increase; 95% CI: 0.15 to 0.71; p  0.005) (14).
lthough these data allow risk estimation of symptom
evelopment, there are no echocardiographic parameters to
stimate the timing of symptom onset.
xercise stress testing. Das et al. (73) prospectively eval-
ated 125 patients with asymptomatic mild (n  11),
oderate (n  62), and severe AS (n  52) to assess the
ccuracy of treadmill exercise testing in predicting symptom
nset within 12 months. Twenty-one patients with a
ositive stress test met the combined end points of sponta-
eous exertional symptoms or cardiac death. Symptom-free
urvival at 12 months was 49% versus 89% for patients with
symptom limited exercise test compared with those
ithout a symptom limited exercise test. In a multivariate
nalysis only the development of symptoms during stress
esting was found to predict symptom onset within 12
onths (odds ratio [OR]: 7.7; 95% CI: 2.79 to 21.39; p 
evere Aortic Stenosis
ean gradient of 80 and 44 mm Hg, respectively. Pulsed wave tissue Doppler
lic longitudinal relaxation velocity (5 cm/s). Longitudinal strain obtained by
ak longitudinal strain (C and D) from apical (green curve), mid (yellow curve),
Dotted white line (D) also shows a reduced global longitudinal strain averaged
te diastolic annular velocity; Ea  peak early diastolic annular velocity; Sa atic S
and m
diasto
ted pe
10%).
eak la.001). Analysis of the patient subgroup with severe AS
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Asymptomatic Severe Aortic Stenosis October 14, 2008:1279–92n  52) showed a positive and negative predictive accuracy
f 65% and 73%, respectively, for subsequent symptom
evelopment after a symptom limited exercise test. Inter-
Figure 3 Exaggerated LV Twist Mechanics in Aortic Stenosis
Peak counterclockwise rotation from apex (A) and clockwise rotation from base (B
views of the patient shown in Figure 2. The difference of the 2 rotational values pr
rotation, particularly near the LV base with relatively high net LV twist angle value.
redictors of High-Risk Patients With Asymptomatic Severe AS
Table 3 Predictors of High-Risk Patients With Asymptomatic S
Parame
Symptom predictor
LV hypertrophy by ECG (14) Present
Peak aortic jet velocity (14) 4.5 m/s
AVA decrease (14) Per 0.2 cm
AVA (14) Per 1 cm2
Exercise stress test (73) Positive
N-terminal BNP (75) NA
Outcome predictor
Age (11) 50 yrs
Baseline functional status score (43) NA
Baseline aortic jet velocity (14) 4.5 m/s
Rate of aortic jet velocity change over time (11) NA
LVEF (42) 50%
AVA decrease (14) Per 0.2 cm
Stroke-work loss index (77) NA
Exercise stress test (78) Present
Resting to peak exercise mean aortic transvalvular gradient (79) 18 mm
Aortic valve calcification by EBCT (80) Per 100 A
Outcome predictor low-gradient AS
Contractile reserve (106) Present
BNP (108) 550 pg/
Operative mortality predictor low-gradient AS
Contractile reserve (106) Absent
Baseline mean transaortic gradient (106) 20 mm
umbers in parentheses are the respective references.
1  increase; 2  decrease; AS  aortic stenosis; AU  Agatston unit; AVA  aortic valve ar
lectrocardiography; HR  hazard ratio; LV  left ventricular; LVEF  left ventricular ejection fraction; NAstingly, however, the type of exercise-induced symptom
eems to be important: compared with breathlessness or
hest tightness, exertional dizziness seems to be a relatively
obtained by speckle track imaging (2D strain, GE Healthcare) of LV short-axis
the peak net twist angle. This example illustrates presence of exaggerated LV
aortic valve closure; LV  left ventricle.
AS
Statistical Test Result 95% Confidence Interval p Value
HR 1.39 1.02–1.89 0.04
RR 1.34 1.04–1.72 0.03
RR 1.26 1.08–1.47 0.004
HR 0.33 0.15–0.71 0.005
OR 7.7 2.79–21.39 0.001
RR 1.48 1.20–1.81 0.0002
RR 5.6 1.46–21.3 0.01
RR 1.2 1.06–1.36 0.006
RR 1.06 1.02–1.10 0.001
HR 0.4 0.23–0.69 0.001
OR 10.9 2.6–43.4 0.001
OR 4.7 1.1–21 0.04) are
ovides
AVC evere
ter
22
1
22
Hg
U1
ml
Hgea; BNP  brain natriuretic peptide; EBCT  electron beam computed tomography; ECG 
 data not available; OR  odds ratio; RR  relative risk.
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October 14, 2008:1279–92 Asymptomatic Severe Aortic Stenosiseliable marker for subsequent symptom development (54%
s. 50% vs. 83%). Breathlessness and chest tightness seem to
e nonspecific symptoms secondary to physical fitness and
xercise tolerance rather than AS. Accordingly, stress test-
ng has been found to be of higher diagnostic value in
atients 70 years old in specific activity scale class I (
atient can complete any activity requiring 7 metabolic
quivalents [74]) (Table 4).
ardiac biomarkers. Bergler-Klein et al. (75) reported that
symptomatic severe AS patients with brain natriuretic
eptide (BNP) or N-terminal BNP concentrations of 130
g/ml and 80 pmol/l, respectively, had a 9-month
ymptom-free survival of close to 90%. Patients with higher
atriuretic peptide concentrations frequently required sur-
ery (symptom-free survival 50%). Kaplan-Meier analysis
n patients with BNP levels 130 pg/ml (n  25) versus
130 pg/ml (n  18) showed symptom-free survival of
00% versus 94  5% at 3 months, 90  7% versus 64 
2% at 6 months, 90  7% versus 45  14% at 9 months,
nd 66  16% versus 34  14% at 12 months (p  0.05).
nly N-terminal BNP independently predicted symptom-
ree survival. Asymptomatic status was defined as freedom
f shortness of breath, angina, dizziness, and syncope with
xertion and symptom status assessed blinded to the results
f BNP and N-terminal BNP. Serial measurements of these
arkers might therefore add incremental information to
elp to identify optimal AVR timing (15).
redictors of Clinical Outcome
linical parameters. Age: event-free survival (AVR, car-
iac death, noncardiac death) for patients with asymptom-
tic severe AS and age 50 years or younger has been found
o be significantly higher (85  6% vs. 59  6% at 1 year,
9  8% vs. 49  6% at 2 years, and 59  9% vs. 21  5%
t 4 years [p  0.001]) (11). Baseline functional status score:
n a multivariate regression analysis model, Otto et al. (43)
howed that the baseline Functional Status Questionnaire (76)
core was predictive of clinical outcome (p  0.002) (43).
atients who remained asymptomatic during follow-up had a
ignificantly higher baseline and final Functional Status
uestionnaire score (96  7%; 95  7%) compared with
hose meeting a clinical end point (92  2%; 85  16%)
patient population included asymptomatic patients with
alue of Exercise Testing to Predict Symptom Onset Within 12 Mo
Table 4 Value of Exercise Testing to Predict Symptom Onset W
Sensiti
Limiting symptoms (chest tightness/dizziness/breathlessness) 7
Age 70 yrs in specific activity scale class I and limiting symptoms 6
Systolic blood pressure decline of 20 mm Hg from baseline 3
ST-segment depression 2 mm 4
dapted from Das et al. (73).ess than severe AS and BAV disease) (43). Achocardiography. Baseline aortic jet velocity, the rate of
hange over time in aortic jet velocity, and baseline AVA
ave been found to predict clinical outcome (AVR, cardiac
eath) (43).
Patients with a baseline aortic jet velocity below 3.0 m/s
nd between 3.0 and 4.0 m/s have a 2-year event-free
urvival (without AVR) of 84  16% and 66  13%,
espectively. Patients with an aortic jet velocity 4.0 m/s
ad a 21  18% likelihood of being alive at 2 years (patient
opulation included asymptomatic patients with less than
evere AS and BAV disease) (43). Compared with patients
ith asymptomatic severe AS and a peak aortic jet velocity
4.5 m/s, patients with asymptomatic severe AS and a peak
ortic jet velocity of 4.5 m/s have an increased RR of a
ardiac event (AVR; cardiac death; RR: 1.48; 95% CI: 1.20
o 1.81; p  0.0002) (14).
Aortic-jet velocity progression is significantly higher in
atients with asymptomatic severe AS and cardiac events
AVR; cardiac death; noncardiac death) compared with
hose without a cardiac event (0.45  0.38 m/s/year vs.
.14  0.18 m/s/year, p  0.001) (11).
Patients with asymptomatic severe AS and a reduced
VEF (50%) have been found to have a higher RR of
ustaining cardiac events (AVR; cardiac death second to AS;
R: 5.6; 95% CI: 1.46 to 21.3; p  0.01) (42).
With regard to AVA, the RR of a cardiac event (AVR;
ardiac death) has been found to increase per 0.2-cm2
ecrease in AVA (RR: 1.20; 95% CI: 1.06 to 1.36; p 
.006) (14).
Event-free survival (AVR; cardiac death; noncardiac
eath) for patients without or with mild calcification versus
atients with moderate or severe calcification has been
ound to be 92  5% versus 60  6% at 1 year, 84  8%
ersus 47  6% at 2 years, and 75  9% versus 20  5% at
years (p  0.001) (11).
Stroke-work loss, the ratio of the mean transvalvular
ressure gradient and LV pressure, has also been proposed
o predict cardiac events (AVR; cardiac death) in asymp-
omatic AS patients. A stroke-work loss 26% results in a
robability of cardiac death or AVR of 30% in the
ollowing 3 months (77).
xercise stress testing. Several studies have evaluated the
alue of exercise stress testing in predicting clinical outcome
n asymptomatic severe AS (Table 5). Amato et al. (78)
rospectively followed 66 patients with asymptomatic severe
in Patients With Aortic Stenosis
12 Months in Patients With Aortic Stenosis
) Specificity (%)
Positive Predictive
Accuracy (%)
Negative Predictive
Accuracy (%)
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Asymptomatic Severe Aortic Stenosis October 14, 2008:1279–92onths. Patients with a positive stress test (n  44) had a
-year event-free survival of only 19% compared with 85%
f symptom-free during exercise. It is important to point out
hat event-free survival was defined as absence of symptoms in
aily life and/or sudden death. Thirty-five patients met the
ombined end points (symptom development n  31; sudden
ardiac death n 4). Positive and negative predictive values for
positive stress test and subsequent end point development
ere 0.79 and 0.86, respectively. The estimated risk to reach
he combined end point for patients with a positive stress test
as 7.6 times higher than in patients with a negative stress test.
very patient who died during the study follow-up had an
VA 0.7 cm2. It seems reasonable to conclude that patients
ith a negative exercise test seem to have a good outcome and
ight not require AVR.
xercise stress echocardiography. Lancellotti et al. (79)
ecently evaluated the incremental prognostic information
f quantitative exercise Doppler echocardiography over
linical, resting echocardiographic, and stress electrocardio-
raphic parameters in patients with asymptomatic severe
S. Resting to peak exercise increase of mean aortic
ransvalvular gradient of 18 mm Hg and an AVA 0.75
m2 were found to independently predict cardiac events
angina, dyspnea, and syncope; hospital admission for heart
ailure; cardiac death; AVR).
lectron-beam computed tomography. Like Rosenhek
t al., Messika-Zeitoun et al. (80) observed that aortic valve
alcification predicted event-free survival defined as survival
ithout dyspnea, angina, syncope, heart failure, or need for
urgery. Adjusted RR was 1.06 (95% CI: 1.02 to 1.10) per
00-Agatston units increment (p  0.001). Event-free
urvival at 5 years was 92 4% versus 40 18% comparing
ummary of Exercise Stress Testing Studies in Asymptomatic Seve
Table 5 Summary of Exercise Stress Testing Studies in Asymp
n Age (yrs) AS Grading Tes
Lancellotti et al. (79) 69 66 12 AVA 1 cm2 Semi-s
on
Das et al. (73) 125 65 (range:
56–74)
Mild (n  11;
EOA 1.2 cm2); moderate
(n  62; EOA
0.8–1.2 cm2); severe
(n  52; EOA 0.8 cm2)
Treadm
Amato et al. (78) 66 49 14.9 AVA 1 cm2 Treadm
mo
f available, data are presented as mean  SD.
AS aortic stenosis; AVA aortic valve area; AVR aortic valve replacement; CV cardiovascuatients with calcification below and above 500 Agatston tnits, respectively (p  0.0002). Aortic valve calcification
lso independently predicted event-free survival in patients
ith no or minimal symptoms (RR: 1.09/100 Agatston
nits; 95% CI: 1.05 to 1.15; p  0.0001). Data further
upporting the predictive value of calcification were recently
eported by Feuchtner et al. (81). Electron-beam computed
omography offers the advantage of objective calcification
uantification (in Agatston units) as compared with the
ubjective grading by echocardiography.
When interpreting predictors of clinical outcome it is
mportant to remember that survival outcomes included
VR as a clinical event, creating the conundrum that AVR
s predictive of AVR.
anagement of Patients
ith Asymptomatic Severe AS
nset of symptoms in a patient with AS who has been
reviously asymptomatic, if unnoticed even only for a few
onths, carries a bleak prognosis (6,13). Therefore, every
atient with asymptomatic severe AS should be educated
nd advised to self-report onset of new symptoms (10).
ome patients might subconsciously adapt and reduce their
aily activities, and in these spuriously “asymptomatic” AS
atients exercise stress testing has been shown to uncover
ymptoms in more than one-third of patients (73). There
re, however, caveats in exercise stress testing symptom
nterpretation: 1) concurrent or unsuspected coronary artery
isease potentially mimics AS symptoms (angina) (10); and
) physical fitness influences reliable AS symptom interpre-
ation. Close clinical follow-up in any patient with asymp-
omatic severe AS is recommended (6 to 12 months), and if
tic Severe AS
ality Criteria for Positive Stress Test
Follow-Up
(Months)
Combined
End Points
bicycle
table
1 of: angina; dyspnea; 2 mm
ST-segment depression; fall or
small rise in SBP compared with
baseline (20 mm Hg); significant
arrhythmias
15 7 Angina; dyspnea;
syncope;
hospital
admission for
heart failure;
cardiac death;
need for AVR
Stopped prematurely due to:
breathlessness; chest discomfort;
dizziness; ST-segment depression
5 mm; 3 consecutive VPCs;
SBP decline 20 mm Hg from
baseline
12 Spontaneous
exertional
symptoms or
CV death
h
mp
Horizontal or downsloping ST-segment
depression 1 mm in men or
2 mm in women, or an upsloping
ST-segment depression 3 mm in
men; precordial chest pain or near
syncope; complex ventricular
arrhythmias; SBP raise from
baseline 20 mm Hg
15 12 Symptoms in
daily life and
or sudden
death
 effective orifice area; SBP systolic blood pressure; VPC ventricular premature contraction.re AS
toma
t Mod
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October 14, 2008:1279–92 Asymptomatic Severe Aortic Stenosisn 2 independent evaluations performed 6 months apart,
atients should continue to follow up clinically with an
nnual echocardiographic examination. Expedited patient
e-evaluation is warranted if there is a change in clinical
tatus (10,82). Hypertension is common in patients with
evere AS (approximately 30%) and should be aggressively
reated in patients with asymptomatic AS (83). There is
imited information regarding the role of statin therapy in
elaying progression of asymptomatic AS (26–30). Two
arge, multicenter, double blinded, randomized, placebo-
ontrolled trials—1) SEAS (Simvastatin and Ezetimibe in
S) and 2) ASTRONOMER (Aortic Stenosis Progression
bservation: Measuring Effect of Rosuvastatin)—will
opefully clarify the role of statins in calcific AS.
Figure 4 Stepwise Evaluation of Patients With Severe AS on th
Levels of evidence are provided in parentheses (American College of Cardiology/A
AS  aortic stenosis; AVA  aortic valve area; AVR  aortic valve replacement; B
grafting; CAD  coronary artery disease; CR  contractile reserve; EBCT  electro
fraction.Figure 4 provides a suggested stepwise approach in
anaging patients with asymptomatic severe AS on the basis
f current American (American College of Cardiology/
merican Heart Association [ACC/AHA]) (10) and Eu-
opean (European Society of Cardiology) (84) AVR guide-
ines. It is worthwhile pointing out that even the recom-
endations with current best evidence are mainly based on
xpert consensus and/or small studies, retrospective studies,
nd registries.
enefits, Risks, and Alternatives to AVR
re-emptive AVR in asymptomatic severe AS could theo-
etically reduce progressive myocardial dysfunction, which
sis of ACC/AHA and ESC Recommendations
n Heart Association [ACC/AHA]; European Society of Cardiology [ESC]) (10,84).
rain natriuretic peptide; BP  blood pressure; CABG  coronary artery bypass
m computed tomography; LV  left ventricle; LVEF  left ventricular ejectione Ba
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fter AVR (85). Iung et al. (86) speculated that nearly
ne-third of patients with symptomatic severe, single-valve
eart disease who could benefit from AVR do not undergo
urgical repair. Timely surgery at an asymptomatic stage
ould therefore potentially reduce the likelihood of being
eemed a nonsurgical candidate when symptomatic.
Potential benefits of AVR in asymptomatic severe AS
ave to be weighed against short-term perioperative risks
nd the long-term risks of thromboembolism, anticoagulation-
elated bleeding, and infective endocarditis. Although no
ntervention, but observation only, has low risks (sudden
ardiac death 1%/year), average surgical mortality for
solated AVR is approximately 3% to 4% (86) and 1% to 2%
n high-volume and experienced medical centers (10). Sur-
ical mortality, however, increases progressively with age
nd is up to 9% in octogenarians (87–92). Additional factors
an further increase the risk of operative mortality in
symptomatic severe AS (e.g., emergent surgery, LV dys-
unction, pulmonary hypertension, coexisting coronary ar-
ery disease, and previous bypass or valve surgery) (84). The
CC/AHA guidelines make the choice of AVR prosthesis
ype dependent on concurrent mitral or tricuspid mechan-
cal valve, anticoagulation contraindications, thrombosis
isk, and patient preferences (10). The incidence of throm-
oembolism and bleeding related to anticoagulation in the
etting of a mechanical aortic valve prosthesis is 1.1 and
.6/100 patient-years, respectively (93), with the latter
ncreasing significantly if patients are 75 years of age (94).
he incidence of infective endocarditis has been reported to
e 0.27%/patient-year (95). These specific incidence rates,
owever, vary depending on the type of mechanical aortic
alve prosthesis (96). Bioprosthetic aortic valves have the
ain risk of structural valve degeneration and therefore
educed valve life. Interestingly, however, a recent meta-
nalysis did not find any differences in mortality in patients
ith mechanical or bioprosthetic aortic valves (97). A
ioprosthetic aortic valve is currently a reasonable choice in
dult patients (approximately 65 years of age) who have
ontraindications to anticoagulation or who decline or do
ot require anticoagulation (10).
Aortic balloon valvotomy as an alternative to AVR is
ssociated with significant procedural risk (98) and resteno-
is (99) and is currently only recommended for the unstable,
everely comorbid adult patient with severe AS (10). In
ontrast, percutaneous AVR has attracted an unprecedented
nterest (100). One can speculate that the role of percuta-
eous AVR might be expanded to patients with asymptom-
tic severe AS who are “assumed” to be high-risk candidates
or surgical AVR; however, this will need to be addressed in
uture studies.
elected Clinical Scenarios
he asymptomatic patient with less than severe AS.
anagement of the asymptomatic patient with less thanevere AS is challenging, and evidence to support “pre- cmptive” AVR is limited. Current guidelines support AVR
uring coronary artery bypass grafting or ascending aorta
urgery in: 1) patients with asymptomatic moderate AS
Class IIa-B); and 2) patients with mild AS and potential
apid AS progression (Class IIb-C) (10). Serial echocardio-
raphic examinations might identify such “rapid progressors,” a
igh-risk group of patients with moderately or severely calci-
ed aortic valves in whom aortic jet velocity increases by 0.3
/s within 1 year (2-year risk of AVR or death of 79%) (11).
he comorbid patient. Patients with asymptomatic and
oderate-to-severe AS and progressive medical comorbidi-
ies (e.g., advanced age and impaired renal function) might
e deemed inoperable once AVR is indicated (86). Pre-
mptive AVR might be justified in some of these patients
ven at an asymptomatic stage. However, management
trategies should be based on thorough risk estimation in
egard to symptom development and AS progression (“rapid
rogressors”), medical center experience and surgery vol-
me, and potential post-AVR benefit (e.g., reversibility/
tabilization of renal function).
he patient in need of noncardiac surgery. Patients with
symptomatic severe AS who require emergent noncardiac
urgery should proceed without AVR evaluation; in elective
oncardiac surgery AVR management is dependent on
oronary artery status (101). Depending on the type of
oncardiac surgery and need for anticoagulation, AVR
ight be performed pre-emptively or simultaneously.
AV disease. BAV disease is a disease of the aortic valve
nd ascending aorta (102) and frequently progresses to AS
18,103). Ascending aortic dilation is independent of AS
everity (102) and affects up to 4 of 10 BAV patients over
ime (104). The most severe risk of aortic dilation, aortic
issection, has been reported to be 9 times higher in BAV
ompared with patients with tricuspid aortic valves (105).
vidence is scarce, but it seems reasonable to manage BAV
atients similar to their tricuspid counterparts with the
ollowing additional criteria for follow-up of ascending
orta dilation. Aortic valve replacement should be consid-
red if indicated by ACC/AHA (10) and European Society
f Cardiology (84) guidelines with the addition of aortic
oot repair or ascending aorta replacement if more than 4.5
m in diameter. Conversely, the aortic valve should be
eplaced in an asymptomatic patient with moderate or
evere AS if aortic root repair or ascending aorta replace-
ent is indicated due to ascending aorta diameter (5.0
m) or diameter increase by 0.5 cm/year or more (cut-off
alues should be adjusted depending on body stature) (10).
ow-gradient/low-flow AS. Patients with severe AS
ight have low-flow/low-gradient (40 mm Hg) AS in the
etting of reduced LVEF or preserved LVEF. Patients with
evere AS and reduced LVEF are rarely asymptomatic, and
herefore most of the available management data are derived
rom symptomatic patients (106–108). In patients with
educed LVEF it is important to determine whether the
ompromised LV function is attributable to a primary
ardiomyopathy (e.g., scarred, fibrosed myocardium), isch-
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October 14, 2008:1279–92 Asymptomatic Severe Aortic Stenosismic LV dysfunction, or excessive afterload ( true, fixed
S), because the latter group of patients are most likely to
enefit from AVR. Low-dose dobutamine stress hemody-
amic echocardiography (20 g/kg/min) identifies these
atients by demonstrating contractile reserve (CR) (defined
s a20% stroke volume increase from baseline on the basis
f LV outflow Doppler measurements [109]) and transval-
ular gradient increase (confirming severe AS). Monin et al.
106) reported that presence of LV contractile reserve is
redictive for long-term survival (HR: 0.40; 95% CI: 0.23 to
.69; p  0.001). Absence of contractile reserve (OR: 10.9;
5% CI: 2.6 to 43.4; p  0.001) and a baseline mean
ransaortic gradient 20 mm Hg (OR: 4.7; 95% CI: 1.1 to
1.0; p  0.04) predicted perioperative mortality. Evidence
or contractile reserve resulted in reduced pre-operative
ortality (CR vs. CR: 5% vs. 32%) (106). Recovery of
VEF and post-operative 2-year survival in the absence
f baseline contractile reserve, however, resembles that of
atients with contractile reserve once patients survive 30
ays after surgery (107). Therefore, AVR should not be
ontraindicated on the basis of documentation of exhausted
ontractile reserve alone. Bergler-Klein et al. (108) evaluated
he prognostic value of BNP in 69 patients with low-flow,
ow-gradient AS, 7 (10%) of whom were New York Heart
ssociation functional class I. One year after AVR, survival
as markedly lower in patients with BNP 550 pg/ml
53  13% vs. 92  7%). Thus, BNP 550 pg/ml emerged
s a significant predictor of outcome (p  0.001). One has
o note that patient numbers were low (n  29), allowing
nly univariate analysis of BNP as a predictor of outcome.
evertheless, these results could support AVR in patients
ith asymptomatic AS and reduced LVEF, even in the
bsence of contractile reserve if BNP levels are550 pg/ml.
Low-flow severe AS patients have increased global LV
fterload leading to pronounced LV concentric remodeling
nd a preserved LVEF, concealing impaired myocardial
unction (110). In this patient group, low stroke volumes
eveal myocardial dysfunction and, due to reduced mean and
aximal flow velocities and gradients (111), might lead to
iscrepantly low mean transvalvular gradients compared
ith AVA (112). The exact prevalence and management of
symptomatic patients with low-flow/low-gradient, severe
S and preserved LVEF is less clear. However, a recent
etrospective study by Hachicha et al. (113) reported that
VR in these patients led to significantly improved survival
nd was preferable to medical treatment. The exact rele-
ance of this finding for patients with asymptomatic severe
S who have low flow despite preserved LVEF remains to
e established.
ummary
n asymptomatic patients with severe AS, AVR mortality
nd the yearly risks of prosthetic valve complications are
reater than the yearly risks of watchful waiting. However,
uch patients must be closely monitored by regular clinicalnd echocardiographic follow-up and should be educated
egarding symptom recognition and prompt self-reporting.
xercise stress testing should be considered if symptom
tatus is unclear. Expedited AVR seems reasonable in
atients with a higher risk profile (extensive aortic valve
alcification, rapid aortic jet progression on serial echocar-
iograms, concomitant coronary artery disease, LV systolic
ysfunction, elevated BNP levels, and in some cases before
eferral for major elective noncardiac surgery). Pre-emptive
VR might emerge as the treatment of choice in the future;
owever, this will be dependent on the (yet unproven)
uperiority of noninvasive myocardial function assessment
nd advances in prosthetic aortic valve design and percuta-
eous valve placement.
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